
Eli Lilly and Co Stock Rises 11% as Experimental Alzheimer’s Drug Slows Rate of Decline in Trial
The next step will be a trial with 500 patients included. Eli Lilly and Co is planning to replicate the results and continue to research the drug’s effectiveness.